Resource Use and Care Quality Differences Among Medicare Beneficiaries Undergoing Chemotherapy
JAMA Network Open · 20.09.2024 · 7 (9) · e2434707
DOI: 10.1001/jamanetworkopen.2024.34707 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 20.09.2024. Verfasst von Yamini Kalidindi und 5 weiteren Autor:innen. Beteiligte Einrichtung: McDermott+ Consulting, Washington, DC. Hauptthemen laut MEDLINE: Neoplasms, Quality of Health Care, Medicare Part C, Medicare. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Medicare Advantage (MA) has grown significantly over the last decade; however, MA’s performance for patients with serious conditions, such as cancer, remains unclear.
Objective
To compare resource use and care quality between MA and traditional Medicare (TM) beneficiaries undergoing cancer chemotherapy. Design, Setting, and Participants This cohort study used TM claims and MA encounter records from January 2015 to December 2019. Participants were MA and TM beneficiaries who initiated cancer chemotherapy between January 2016 and July 2019. Inverse probability of treatment weighting balanced characteristics between MA and TM beneficiaries, and regression estimation was used. The analysis was conducted between August 2023 and May 2024. Exposure Chemotherapy initiation after a 1-year washout period. Main Outcomes and Measures Resource use and care quality were measured during a 6-month period following chemotherapy initiation. Resource use was measured using standardized prices for services in both MA and TM, covering hospital inpatient services, outpatient care, Part D drugs, and hospice services. Chemotherapy utilization was examined for Part B chemotherapy, Part B supportive drugs, and Part D chemotherapy. Quality measures included chemotherapy-related emergency department (ED) visits and hospitalizations, avoidable ED visits, preventable hospitalizations during the 6-month episode, and survival days up to 18 months from chemotherapy initiation.
Results
The study comprised 122 966 MA enrollees contributing to 125 518 episodes (mean [SD] age, 73.2 [7.6] years; 68 479 [54.6%] female; 8900 [7.1%] Hispanic, 18 423 [14.7%] non-Hispanic Black, and 94 817 [75.5%] non-Hispanic White participants) and 274 666 TM beneficiaries, contributing 282 200 episodes (mean [SD] age, 73.1 [8.4] years; 155 709 [55.2%] female; 10 666 [3.8%] Hispanic, 22 088 [7.8%] non-Hispanic Black, and 241 113 [85.4%] non-Hispanic White participants). Adjusted total resource use per enrollee during the 6-month episode was $8498 (95% CI, $8178 to $8817) lower in MA than TM ($61 004 vs $69 502). Part B chemotherapy resource use accounted for most of the difference in total resource use, with MA enrollees having $4765 (95% CI, $4547 to $4982) lower use than TM beneficiaries. Lower resource use for Part B chemotherapy in MA was associated with 1.03 fewer chemotherapy visits (95% CI, 0.99 to 1.06 visits) and $277 (95% CI, $183 to $272) less expensive chemotherapy per visit. Findings on quality were mixed, but importantly, survival did not differ between MA and TM patients who initiated chemotherapy. Conclusions and Relevance In this cohort study of Medicare beneficiaries with cancer undergoing chemotherapy, MA enrollment was associated with lower resource use but not shorter survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- McDermott+ Consulting, Washington, DC.
- Department of Health Administration and Policy, College of Public Health, George Mason University, Fairfax, Virginia.
- Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis.
- Department of Family Medicine and Community Health, University of Minnesota, Minneapolis.
- Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
- NIA NIH HHS
Zitieren
APA
Kalidindi, Y., Jung, J., Feldman, R., Carlin, C., Song, G., & Mitchell, A. (2024). Resource Use and Care Quality Differences Among Medicare Beneficiaries Undergoing Chemotherapy. JAMA Network Open, 7(9), e2434707. https://doi.org/10.1001/jamanetworkopen.2024.34707
Vancouver
Kalidindi Y, Jung J, Feldman R, Carlin C, Song G, Mitchell A. Resource Use and Care Quality Differences Among Medicare Beneficiaries Undergoing Chemotherapy. JAMA Network Open. 2024;7(9):e2434707. doi:10.1001/jamanetworkopen.2024.34707
BibTeX
@article{Kalidindi2024,
author = {Kalidindi, Yamini and Jung, Jeah and Feldman, Roger and Carlin, Caroline and Song, Ge and Mitchell, Aaron},
title = {Resource Use and Care Quality Differences Among Medicare Beneficiaries Undergoing Chemotherapy},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {9},
pages = {e2434707},
doi = {10.1001/jamanetworkopen.2024.34707}
}
EUVIMED